
|Videos|May 18, 2023
Overview of the EMERALD Trial of Elacestrant in ER+, HER2- Advanced Breast Cancer
The Oncology Brothers are joined by Virginia Kaklamani, MD, DSc, who provides an overview of the EMERALD trial design and use of elacestrant in ER+, HER2- advanced breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Allogeneic CD70 CAR T-Cell Therapy Shows Activity in Refractory Kidney Cancer
2
Indefinite Myeloma Maintenance Shows No OS Benefit vs 2-Year Duration
3
Pembrolizumab Plus Denosumab Shows Activity in Pretreated Kidney Cancer
4
Final RELEVANCE Data Affirm R2 as Chemo-Free Alternative in Untreated FL
5


























